Agios Pharmaceuticals (NASDAQ:AGIO) Shares Break Above 200-Day Moving Average - Should You Sell?

Key Points

• Agios shares moved above their 200-day moving average, trading as high as $33.12 and last at $32.82, versus the average of $31.82.
• Analysts have a Moderate Buy consensus and an average price target of $42.12. HC Wainwright raised its target to $62 and reiterated its Buy rating, while Truist cut its target to $35 but kept a Buy rating.
• In its latest quarter, Agios reported a loss of $1.09 per share, narrower than the $1.24 loss analysts expected, and revenue of $55.39 million, above estimates of $51.65 million.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) shares crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $31.82 and traded as high as $33.12. Agios Pharmaceuticals shares last traded at $32.82, with a volume of 844,737 shares changing hands.

Key Stories Impacting Agios Pharmaceuticals

Here are a few of the latest stories about AGIO:

• Positive Sentiment: HC Wainwright raised its EPS estimates across 2026–2030, projecting losses to narrow and turning profitable in 2030, with EPS of $2.01 versus its earlier $0.72 estimate. The firm reiterated its Buy rating and $62 price target. Agios Pharmaceuticals analyst estimates
• Neutral Sentiment: A report described a sharp increase in short interest but also stated that short interest totaled zero shares, making the data internally inconsistent; it does not establish meaningful short-selling pressure. Agios Pharmaceuticals short-interest information
• Neutral Sentiment: Agios published its Q3 2026 earnings-call presentation, but the supplied entry contains no details about the results or guidance, so its market implications cannot be assessed from this information. Agios Pharmaceuticals Q3 2026 earnings-call presentation

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on AGIO shares. Truist Financial lowered their price objective on shares of Agios Pharmaceuticals from $37.00 to $35.00 and set a "buy" rating on the stock in a research report on Friday, November 6th. JPMorgan Chase & Co. increased their price objective on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a "neutral" rating in a report on Friday, August 7th. Weiss Ratings downgraded shares of Agios Pharmaceuticals from a "sell (d)" rating to a "sell (d-)" rating in a research note on Monday. HC Wainwright raised their price objective on shares of Agios Pharmaceuticals from $55.00 to $62.00 and gave the stock a "buy" rating in a report on Friday, November 6th. Finally, TD Cowen raised Agios Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $42.12.

Agios Pharmaceuticals Price Performance

The firm has a market cap of $1.96 billion, a PE ratio of -5.19 and a beta of 0.66. The firm has a 50-day simple moving average of $33.17 and a 200 day simple moving average of $31.82.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $0.15. The company had revenue of $55.39 million during the quarter, compared to analyst estimates of $51.65 million. Agios Pharmaceuticals had a negative net margin of 264.76% and a negative return on equity of 34.63%. Sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -5.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Sarah Gheuens sold 7,866 shares of the firm's stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $37.69, for a total transaction of $296,469.54. Following the completion of the transaction, the insider owned 54,645 shares of the company's stock, valued at $2,059,570.05. This trade represents a 12.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 9,855 shares of company stock worth $371,112. 5.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in AGIO. Nykredit A S purchased a new stake in Agios Pharmaceuticals during the 2nd quarter valued at $26,000. Three Bridge Wealth Advisors LLC bought a new position in shares of Agios Pharmaceuticals during the third quarter valued at $27,000. Quantbot Technologies LP purchased a new stake in shares of Agios Pharmaceuticals during the second quarter valued at $43,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Agios Pharmaceuticals during the second quarter valued at $47,000. Finally, Allworth Financial LP purchased a new stake in shares of Agios Pharmaceuticals during the second quarter valued at $73,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals is a biopharmaceutical company focused on developing medicines for rare genetic diseases, particularly blood disorders. Based in Cambridge, Massachusetts, the company applies research into cellular metabolism to identify potential treatments. Its marketed medicine, PYRUKYND (mitapivat), is approved in the United States to treat adults with pyruvate kinase deficiency, a rare inherited disorder that can cause anemia. Agios also develops therapies for other rare diseases, including additional blood disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.